Effects of Mesalamine Combined with Live Combined Bifidobacterium, Lactobacillus and Enterococcus Capsules on Intestinal Mucosa Barrier Function and Intestinal Microbiota in Mildly Active Crohn’s Disease Patients

References

• Petagna L, Antonelli A, Ganini C, et al. Pathophysiology of Crohn’s disease inflammation and recurrence. Biol Direct. 2020;15(1):1. doi:10.1186/s13062-020-00280-5.
   PubMed Web of Science ®Google Scholar
• Veauthier B, Hornecker JR. Crohn’s disease: Diagnosis and management. American Family Physician. 2018;98(11):661–8.
   PubMed Web of Science ®Google Scholar
• Ballester Ferre MP, Bosca-Watts MM, Minguez PM. Crohn’s disease. Medicina Clinica. 2018;151(1):26–33. doi:10.1016/j.medcli.2017.10.036.
   PubMed Web of Science ®Google Scholar
• Cheng WX, Ren Y, Lu MM, et al. Palmitoylation in Crohn’s disease: Current status and future directions. World J Gastroenterol. 2021;27(48):8201–8215. doi:10.3748/wjg.v27.i48.8201.
   PubMed Web of Science ®Google Scholar
• Torres J, Mehandru S, Colombel JF, Peyrin-Biroulet L. Crohn’s disease. Lancet. 2017;389(10080):1741–1755. doi:10.1016/S0140-6736(16)31711-1.
   PubMed Web of Science ®Google Scholar
• Xie J, Huang Y, Wu HG, Li J. Acupuncture and moxibustion for treatment of Crohn’s disease: A brief review. World J Gastroenterol. 2022;28(25):3001–3003. doi:10.3748/wjg.v28.i25.3001.
   PubMed Web of Science ®Google Scholar
• Stenczel ND, Purcarea MR, Tribus LC, Oniga GH. The role of the intestinal ultrasound in Crohn’s disease diagnosis and monitoring. J Med Life. 2021;14(3):310–315. doi:10.25122/jml-2021-0067.
   PubMedGoogle Scholar
• Nakashima J, Preuss CV. Mesalamine (USAN). In: StatPearls; 2023.
   Google Scholar
• Xie C, Quan R, Hong F, Zou K, Yan W, Fu Y. The culprit of mesalamine intolerance: Case series and literature review. BMC Gastroenterol. 2019;19(1):138. doi:10.1186/s12876-019-1049-2.
   PubMedGoogle Scholar
• Tang-Fichaux M, Branchu P, Nougayrede JP, Oswald E. Tackling the threat of cancer due to pathobionts producing colibactin: Is mesalamine the magic bullet? Toxins. 2021;13(12):897. doi:10.3390/toxins13120897.
   PubMed Web of Science ®Google Scholar
• Huang Y, Wu M, Xiao H, Liu H, Yang G. Mesalamine-mediated amelioration of experimental colitis in piglets involves gut microbiota modulation and intestinal immune cell infiltration. Front Immunol. 2022;13:883682. doi:10.3389/fimmu.2022.883682.
   PubMed Web of Science ®Google Scholar
• Yao S, Zhao Z, Wang W, Liu X. Bifidobacterium Longum: Protection against inflammatory bowel disease. J Immunol Res. 2021;2021:8030297–8030211. doi:10.1155/2021/8030297.
   PubMed Web of Science ®Google Scholar
• Huang M, Chen Z, Lang C, et al. Efficacy of mesalazine in combination with bifid triple viable capsules on ulcerative colitis and the resultant effect on the inflammatory factors. Pakistan J Pharma Sci. 2018;31(6(Special):2891–2895.
   PubMed Web of Science ®Google Scholar
• Inflammatory Bowel Disease Group CSoGCMA. Chinese consensus on diagnosis and treatment in inflammatory bowel disease (2018, Beijing). J Digest Dis. 2021;22(6):298–317. doi:10.1111/1751-2980.12994.
   PubMed Web of Science ®Google Scholar
• Best WR, Becktel JM, Singleton JW, Kern F, Jr. Development of a Crohn’s disease activity index. National Cooperative Crohn’s Disease Study. Gastroenterology. 1976;70(3):439–444.
   PubMed Web of Science ®Google Scholar
• Cottone M, Papi C, Orlando A. Infliximab, azathioprine or combination therapy in the treatment of active Crohn’s disease. Expert Rev Gastroenterol Hepatol. 2010;4(6):709–712. doi:10.1586/egh.10.68.
   PubMed Web of Science ®Google Scholar
• Vílchez A, Orts JA, Frédérique Scheirs S, Benavent G. Mesalazine renal lithiasis. Arch Esp Urol. 2020;73(6):561–564.
   PubMed Web of Science ®Google Scholar
• Mehta RS, Mayers JR, Zhang Y, et al. Gut microbial metabolism of 5-ASA diminishes its clinical efficacy in inflammatory bowel disease. Nat Med. 2023;29(3):700–709. doi:10.1038/s41591-023-02217-7.
   PubMed Web of Science ®Google Scholar
• Qian L, Huang J, Qin H. Probiotics and dietary intervention modulate the colonic mucosa-associated microbiota in high-fat diet populations. Turk J Gastroenterol. 2020;31(4):295–304. doi:10.5152/tjg.2020.19013.
   PubMed Web of Science ®Google Scholar
• Fang J, Yang Y, Xie W. Chinese expert consensus on the application of live combined Bifidobacterium, Lactobacillus, and Enterococcus powder/capsule in digestive system diseases (2021). J Gastroenterol Hepatol. 2023;38(7):1089–1098. doi:10.1111/jgh.16195.
   PubMed Web of Science ®Google Scholar
• Li HF, Hu GQ, Liu WW, Chen W. Clinical observation on the inflammatory indexes in septic gastrointestinal dysfunction treated with acupuncture at Jiaji (EX-B 2). Zhongguo Zhen Jiu. 2019;39(10):1055–1058. doi:10.13703/j.0255-2930.2019.10.006.
   PubMedGoogle Scholar
• Su Z, Kang Y. Influences of bifid triple viable capsules plus cetirizine on gut microbiota and immune function in children with eczema. Drug Des Devel Ther. 2022;16:2509–2515. doi:10.2147/DDDT.S363702.
   PubMed Web of Science ®Google Scholar
• Wang W, Zhang H, Huang W. Efficacy of Bifidobacterium triple viable enteric-coated capsules combined with enteral nutrition on patients with chronic critical illness and influence on immune and coagulation function. Evid Based Complement Alternat Med. 2021;2021:3718255. doi:10.1155/2021/3718255.
   PubMed Web of Science ®Google Scholar
• Connolly JG, Goldstone SE. Squamous cell dysplasia in the proximal rectum of three patients treated for ulcerative colitis on immunomodulators. Int J Colorectal Dis. 2017;32(5):753–756. doi:10.1007/s00384-016-2745-9.
   PubMed Web of Science ®Google Scholar